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ABSTRACT
This article reviews the role of inflammation 
in bladder dysfunction, and the potential for 
prostaglandins to play a contributing role. If this 
is the case, it presents this receptor system as a 
future therapeutic target, and also enhances our 
knowledge into the mechanisms underlying lower 
urinary tract function.
Keywords: urinary bladder; inflammatory 
mediators; prostaglandins; prostanoids; histamine.
Urinary bladder inflammation has been observed 
in various lower urinary tract disorders, including 
interstitial cystitis/bladder pain syndrome (IC/BPS)1 
and overactive bladder (OAB)2. There are currently 
limited pharmaceutical options to selectively target 
the inflammation present in either IC/BPS or OAB. 
Antimuscarinic medicines, which act on the activity 
of smooth muscle, have been used as the first-line 
pharmacological treatment for OAB. For IC/BPS, 
treatments such as dimethylsulfoxide (DMSO), a bladder 
instillation that can assist in reducing inflammation 
and pain, as well as pentosan polysulphate, an 
oral medicine which works to protect the bladder 
epithelium, do not act on the associated bladder 
inflammatory mechanisms. This presents opportunities 
for future research to identify novel therapeutic 
approaches for the treatment of IC/BPS and OAB, 
with the target of inhibiting bladder inflammation. As 
such, recent advances in the research surrounding our 
understanding of the role of inflammatory mediators in 
bladder dysfunction warrant a review.
It is reported that there is an increase in the presence 
of inflammatory mediators within the bladder wall3 
and urine4 of patients diagnosed with OAB or IC/
BPS. The mediators include histamine5, nerve growth 
factor, serotonin/5-HT6,7, proteases, chemokines and 
prostaglandins released either from nearby mast cells, 
or synthesised within the cells lining the bladder wall8. 
These reports often correlate to clinical findings, such 
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as where significantly increased expression of histamine 
receptors have been noted in people presenting with 
BPS/IC9. The actions of many inflammatory mediators 
can induce immediate urinary bladder contractions7,10–12 
and sensitise afferent nerve endings to result in an 
increased spinal cord neuronal activation13. This is 
of importance, as inflammatory mediators operate 
upon pathophysiological mechanisms which are 
not targeted by current approved therapies for IC/
BPS nor OAB. There is also increasing evidence that 
the actions of inflammatory mediators are altered in 
ageing14,15. Therefore, inflammation and the actions of 
these pro-inflammatory mediators may contribute to 
the development of the urinary frequency and urgency 
symptoms observed in OAB, and pain in IC/BPS.
All prostaglandins are synthesised from arachidonic 
acid, which is a polyunsaturated omega-6 fatty acid 
released from cell membranes via the hydrolysis of 
the SN-2 bond by the phospholipase A2 enzyme16. 
Two cyclooxygenase isoforms, COX-1 and COX-2, 
metabolise arachidonic acid into prostaglandin H2 
which is subsequently converted into five primary 
prostaglandins via their respective synthases: 
prostaglandin E2, prostaglandin D2, prostaglandin 
F2α, prostaglandin I2
 
(also called prostacyclin) and 
thromboxane. These inflammatory mediators exert 
their functions through the stimulation of eight specific 
guanine nucleotide-binding proteins (G-protein) 
coupled receptors: prostaglandin E2 receptor 1–4 
(EP1–4), prostaglandin D2 receptor (DP), prostaglandin 
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F receptor (FP), prostaglandin I2 receptor (IP) and 
thromboxane receptor (TP), respectively17. G-protein-
coupled receptors are cell membrane proteins that 
convert extracellular signals into intracellular responses. 
These signals include responses to neurotransmitters, 
hormones and chemical mediators like prostaglandins. 
Of the five prostaglandins produced endogenously 
within the bladder wall, prostaglandin E2 is thought to 
be the most likely contributor to bladder dysfunction. 
It is involved in the control of normal continence via 
afferent signalling and the involvement in detrusor 
overactivity has been proposed by its ability to sensitise 
capsaicin-sensitive afferent nerve endings18.
Generally, the stimulation of EP1 and EP3 receptors 
are thought to cause bladder contractions, whereas 
EP2 and EP4 induce bladder relaxation19. Indeed, the 
EP1 receptor is involved in initiating micturition in 
both humans and animals, and has been shown to be 
responsible for OAB in models of bladder obstruction20. 
In the isolated guinea pig bladder, application of 
prostaglandin E2 resulted in increased amplitude of 
urinary bladder phasic contractions without affecting 
the frequency of these contractions21. In studies 
involving pig tissue, treatment with prostaglandin E2 
induced significantly enhanced tonic contractions 
and increased the frequency of phasic contractions 
in both urothelium with lamina propria (U&LP) and 
detrusor smooth muscle tissue strips22, presenting 
as a potentially significant contributor to contractile 
activity. The stretch-induced release of prostaglandin 
E2 from the urothelium has been suggested to exert 
a direct effect upon detrusor smooth muscle cells to 
evoke contractions or to enhance the release of local 
adenosine triphosphate (ATP) via stimulation of EP1 
receptors, resulting in an increased afferent nerve 
activation23 and subsequent signalling. As ATP is 
involved in signalling the sensation of bladder fullness 
to the central nervous system24, increased neuronal 
activation could thus trigger the micturition reflex and 
feelings of urgency, and this provides an interesting 
avenue for future research.
The role of other prostaglandins in the urinary bladder 
has also been explored in the literature, albeit to a 
lesser extent. The major prostaglandin released from 
mast cells at sites of inflammation is prostaglandin D2, 
which has been shown to inhibit nerve stimulation-
induced detrusor smooth muscle contractions in strips 
of guinea pig bladder25. The prostacyclin antagonists 
decrease neurogenic detrusor overactivity in spinal 
cord-injured rats26 by significantly enhancing the 
interval between voiding and voiding volume. Similarly, 
a decrease in the frequency of bladder contractions 
and increased micturition threshold was observed 
in citric acid induced detrusor overactivity27 in the 
presence of prostacyclin antagonist. Thromboxane 
and prostaglandin F2α have been shown to induce 
direct contractions of the isolated human detrusor28 
and U&LP29. However, there remains a great paucity of 
research into the impacts of prostaglandin agonists on 
human tissues, demonstrating a clear need for future 
studies in this area.
U&LP strips taken from the two most superficial 
layers of the bladder lumen are known to exhibit 
spontaneous phasic contractions in the absence of 
any stimulation30. These spontaneous contractions 
are thought to be propagated by the muscularis 
mucosae present within the U&LP31 and are 
capable of modulating the overall bladder function. 
Immunohistochemical analysis has demonstrated 
that this muscularis mucosae layer is distinct from its 
adjacent detrusor smooth muscle layers and has been 
observed in pig, human and guinea pig bladders31. This 
is further reinforced with the observation that U&LP 
preparations continue to develop large spontaneous 
contractions after the apical urothelial layer and larger 
blood vessels are removed32. Nonetheless, these 
spontaneous contractions occurring in rat U&LP arise 
from noradrenaline stimulation of the vasculature33 
which remains similar to that observed in pig tissue34. 
The impact of prostaglandin agonists on U&LP 
contractility and influence to increase the frequency 
of spontaneous phasic contractions and decrease 
the amplitude is of interest, due to growing evidence 
for this system’s role in modulating detrusor smooth 
muscle contractions35. Identifying receptor systems 
capable of modulating bladder activity presents 
the possibility for developing novel therapeutic 
approaches for inhibiting inflammatory mediator-
induced contractile responses.
Of particular interest is histamine, which has been 
shown to increase the frequency of phasic contractions 
and decrease their amplitude in porcine U&LP while 
initiating these phasic contractions in the detrusor5,14. 
The increases in tonic contractions and phasic activity 
observed in response to histamine are comparable to 
those observed after treatment with prostaglandin 
E2. Rahnama’i et al.21 reported that treatment with 
prostaglandin E2 reduced the amplitudes of phasic 
contractions in intact guinea pig bladders. However, the 
link to humans has never been investigated, presenting 
an interesting avenue for research into the potential of 
the histamine and prostaglandin receptor systems to 
underlie some presentations of bladder dysfunctions 
such as OAB and IC/BPS.
From the current literature, the prostaglandin system, 
with a particular interest in EP1 to EP4 receptors, could 
be a novel target for pharmaceutical treatments and 
should be explored further. The mechanism of action 
for these prostaglandin responses may present an 
additional therapeutic target in the treatment of OAB 
or IC/bladder pain syndrome.
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